These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 33783470)

  • 1. Locus coeruleus integrity and the effect of atomoxetine on response inhibition in Parkinson's disease.
    O'Callaghan C; Hezemans FH; Ye R; Rua C; Jones PS; Murley AG; Holland N; Regenthal R; Tsvetanov KA; Wolpe N; Barker RA; Williams-Gray CH; Robbins TW; Passamonti L; Rowe JB
    Brain; 2021 Sep; 144(8):2513-2526. PubMed ID: 33783470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atomoxetine restores the response inhibition network in Parkinson's disease.
    Rae CL; Nombela C; Rodríguez PV; Ye Z; Hughes LE; Jones PS; Ham T; Rittman T; Coyle-Gilchrist I; Regenthal R; Sahakian BJ; Barker RA; Robbins TW; Rowe JB
    Brain; 2016 Aug; 139(Pt 8):2235-48. PubMed ID: 27343257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving response inhibition in Parkinson's disease with atomoxetine.
    Ye Z; Altena E; Nombela C; Housden CR; Maxwell H; Rittman T; Huddleston C; Rae CL; Regenthal R; Sahakian BJ; Barker RA; Robbins TW; Rowe JB
    Biol Psychiatry; 2015 Apr; 77(8):740-8. PubMed ID: 24655598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional locus coeruleus degeneration is uncoupled from noradrenergic terminal loss in Parkinson's disease.
    Doppler CEJ; Kinnerup MB; Brune C; Farrher E; Betts M; Fedorova TD; Schaldemose JL; Knudsen K; Ismail R; Seger AD; Hansen AK; Stær K; Fink GR; Brooks DJ; Nahimi A; Borghammer P; Sommerauer M
    Brain; 2021 Oct; 144(9):2732-2744. PubMed ID: 34196700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting impulsivity in Parkinson's disease using atomoxetine.
    Kehagia AA; Housden CR; Regenthal R; Barker RA; Müller U; Rowe J; Sahakian BJ; Robbins TW
    Brain; 2014 Jul; 137(Pt 7):1986-97. PubMed ID: 24893708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Locus Coeruleus Integrity Is Linked to Response Inhibition Deficits in Parkinson's Disease and Progressive Supranuclear Palsy.
    Ye R; Hezemans FH; O'Callaghan C; Tsvetanov KA; Rua C; Jones PS; Holland N; Malpetti M; Murley AG; Barker RA; Williams-Gray CH; Robbins TW; Passamonti L; Rowe JB
    J Neurosci; 2023 Oct; 43(42):7028-7040. PubMed ID: 37669861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noradrenergic deficits contribute to apathy in Parkinson's disease through the precision of expected outcomes.
    Hezemans FH; Wolpe N; O'Callaghan C; Ye R; Rua C; Jones PS; Murley AG; Holland N; Regenthal R; Tsvetanov KA; Barker RA; Williams-Gray CH; Robbins TW; Passamonti L; Rowe JB
    PLoS Comput Biol; 2022 May; 18(5):e1010079. PubMed ID: 35533200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures.
    Ye Z; Rae CL; Nombela C; Ham T; Rittman T; Jones PS; Rodríguez PV; Coyle-Gilchrist I; Regenthal R; Altena E; Housden CR; Maxwell H; Sahakian BJ; Barker RA; Robbins TW; Rowe JB
    Hum Brain Mapp; 2016 Mar; 37(3):1026-37. PubMed ID: 26757216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the noradrenergic system in Parkinson's disease: an 11C-MeNER PET and neuromelanin MRI study.
    Sommerauer M; Fedorova TD; Hansen AK; Knudsen K; Otto M; Jeppesen J; Frederiksen Y; Blicher JU; Geday J; Nahimi A; Damholdt MF; Brooks DJ; Borghammer P
    Brain; 2018 Feb; 141(2):496-504. PubMed ID: 29272343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mild cognitive impairment in de novo Parkinson's disease: A neuromelanin MRI study in locus coeruleus.
    Li Y; Wang C; Wang J; Zhou Y; Ye F; Zhang Y; Cheng X; Huang Z; Liu K; Fei G; Zhong C; Zeng M; Jin L
    Mov Disord; 2019 Jun; 34(6):884-892. PubMed ID: 30938892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prefrontal Cortical Connectivity Mediates Locus Coeruleus Noradrenergic Regulation of Inhibitory Control in Older Adults.
    Tomassini A; Hezemans FH; Ye R; Tsvetanov KA; Wolpe N; Rowe JB
    J Neurosci; 2022 Apr; 42(16):3484-3493. PubMed ID: 35277392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's Disease.
    Borchert RJ; Rittman T; Passamonti L; Ye Z; Sami S; Jones SP; Nombela C; Vázquez Rodríguez P; Vatansever D; Rae CL; Hughes LE; Robbins TW; Rowe JB
    Neuropsychopharmacology; 2016 Jul; 41(8):2171-7. PubMed ID: 26837463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study.
    Knudsen K; Fedorova TD; Hansen AK; Sommerauer M; Otto M; Svendsen KB; Nahimi A; Stokholm MG; Pavese N; Beier CP; Brooks DJ; Borghammer P
    Lancet Neurol; 2018 Jul; 17(7):618-628. PubMed ID: 29866443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo detection of substantia nigra and locus coeruleus volume loss in Parkinson's disease using neuromelanin-sensitive MRI: Replication in two cohorts.
    Hwang KS; Langley J; Tripathi R; Hu XP; Huddleston DE
    PLoS One; 2023; 18(4):e0282684. PubMed ID: 37053195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noradrenergic alterations in Parkinson's disease: a combined 11C-yohimbine PET/neuromelanin MRI study.
    Laurencin C; Lancelot S; Brosse S; Mérida I; Redouté J; Greusard E; Lamberet L; Liotier V; Le Bars D; Costes N; Thobois S; Boulinguez P; Ballanger B
    Brain; 2024 Apr; 147(4):1377-1388. PubMed ID: 37787503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping the effects of atomoxetine during response inhibition across cortical territories and the locus coeruleus.
    Ye R; Mazibuko N; Teichert J; Regenthal R; Kehagia AA; Mehta MA
    Psychopharmacology (Berl); 2022 Feb; 239(2):365-376. PubMed ID: 34693457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atomoxetine modulates the relationship between perceptual abilities and response bias.
    Guedj C; Reynaud A; Monfardini E; Salemme R; Farnè A; Meunier M; Hadj-Bouziane F
    Psychopharmacology (Berl); 2019 Dec; 236(12):3641-3653. PubMed ID: 31384989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of nicotine and atomoxetine on brain function during response inhibition.
    Kasparbauer AM; Petrovsky N; Schmidt PM; Trautner P; Weber B; Sträter B; Ettinger U
    Eur Neuropsychopharmacol; 2019 Dec; 29(2):235-246. PubMed ID: 30552041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder.
    Chamberlain SR; Del Campo N; Dowson J; Müller U; Clark L; Robbins TW; Sahakian BJ
    Biol Psychiatry; 2007 Nov; 62(9):977-84. PubMed ID: 17644072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Locus coeruleus integrity correlates with inhibitory functions of the fronto-subthalamic 'hyperdirect' pathway in Parkinson's disease.
    Xu B; He T; Lu Y; Jia J; Sahakian BJ; Robbins TW; Jin L; Ye Z
    Neuroimage Clin; 2022; 36():103276. PubMed ID: 36510410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.